Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Reistone Completes $100 Million A Round for Inflammatory Disease Drugs

publication date: Jun 24, 2022

In May, Reistone Biopharma of Shanghai completed a Series A financing of nearly $100 million. Reistone was formed in 2018 and incubated by Jiangsu Hengrui Pharma (SHA: 600275) with the goal of bringing Hengrui’s China-developed inflammatory disease drugs to global markets. Reistone’s lead product is a JKA1 inhibitor in Phase III trial for atopic dermatitis and other immune disorders. Also in May, Hengrui launched another in-house global company, Luzsana Biotechnology, to bring its novel and affordable medications to global markets. Reistone’s A round was led by Huagai Capital and Capital Fund. More details....

Share this with colleagues:  
 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital